Last updated: August 30, 2026
Melphalan hydrochloride is a mature alkylating agent with stable clinical demand but limited market expansion. Revenue is concentrated in high-dose conditioning before autologous stem-cell transplantation and in multiple myeloma treatment. The commercial market divides into low-priced generic melphalan hydrochloride products and premium ready-to-use or reformulated products such as Evomela.
The product’s long-term financial trajectory is likely to be flat to modestly declining in volume, with pricing and formulation mix determining supplier performance. Transplant volumes support baseline demand, while generic competition, alternative conditioning regimens, oral oncology therapies, CAR-T treatment and bispecific antibodies constrain growth.
What is melphalan hydrochloride used for?
Melphalan hydrochloride is an alkylating chemotherapy agent that damages tumor-cell DNA. In the United States, the principal commercial uses are:
- High-dose conditioning before autologous stem-cell transplantation in multiple myeloma.
- Palliative treatment of multiple myeloma.
- Selected off-label uses in conditioning protocols and regional chemotherapy.
Evomela, the branded injectable melphalan hydrochloride product, received FDA approval in October 2016. Its labeled indications are high-dose conditioning before autologous stem-cell transplantation in patients with multiple myeloma and palliative treatment of multiple myeloma [1].
Melphalan hydrochloride is distinct from melphalan flufenamide, marketed as Pepaxto. Pepaxto was a separate product with a different molecular structure, clinical profile and regulatory history. The FDA approved withdrawal of Pepaxto in 2024 after confirmatory-trial concerns, but that action does not remove melphalan hydrochloride from the market [2].
How large is the melphalan hydrochloride market?
No major manufacturer publicly reports global melphalan hydrochloride sales as a standalone category. Public company filings usually aggregate the product within oncology, hospital or specialty-pharmaceutical revenue.
The addressable market is determined by procedure volume rather than by a large chronic-prescription population. The principal demand drivers are:
| Market driver |
Effect on melphalan hydrochloride demand |
| Autologous stem-cell transplant volume |
Supports recurring demand for high-dose injectable melphalan |
| Multiple myeloma incidence |
Expands the underlying treatment population |
| Transplant eligibility |
Limits use to medically suitable patients |
| Generic competition |
Reduces price and increases procurement pressure |
| Ready-to-use formulations |
Supports premium pricing and hospital adoption |
| CAR-T and bispecific therapies |
May reduce transplant use in some treatment sequences |
| Supply reliability |
Can shift hospital purchasing between suppliers |
The transplant segment is the most commercially important. High-dose melphalan remains a standard conditioning regimen for eligible multiple myeloma patients undergoing autologous transplantation, despite the expansion of novel agents and cellular therapies [3].
What is the financial trajectory for melphalan hydrochloride?
The financial trajectory has three distinct stages.
Branded reformulation growth
Evomela created a premium commercial segment by offering a formulation designed to avoid the reconstitution and stability limitations associated with conventional melphalan hydrochloride. Spectrum Pharmaceuticals developed the product and commercialized it after FDA approval. Acrotech Biopharma later acquired Spectrum’s commercial portfolio, including Evomela [4].
The commercial rationale was based on hospital workflow, preparation time, product stability and reduced handling complexity. Those attributes allowed Evomela to compete on total treatment economics rather than on active ingredient cost alone.
Generic price erosion
Generic injectable melphalan products place a ceiling on long-term pricing. Hospitals and group purchasing organizations can substitute products when supply, formulation, concentration and handling requirements are acceptable.
As regulatory exclusivity expired, the market shifted toward a two-tier structure:
- Lower-cost conventional generic melphalan hydrochloride.
- Premium branded or differentiated formulations with operational advantages.
This structure limits unit-price expansion for the active ingredient while preserving higher revenue per dose for products with measurable pharmacy and administration benefits.
Mature-market stabilization
The current market is mature. Revenue stability depends on maintaining transplant volumes, retaining hospital contracts and avoiding supply interruptions. A supplier with a differentiated formulation can defend revenue better than a conventional generic manufacturer, but the total market does not have the characteristics of a high-growth oncology drug.
The most likely financial pattern is:
| Period |
Expected market behavior |
| Pre-2016 |
Established generic and legacy branded demand |
| 2016-2019 |
Premium formulation adoption after Evomela launch |
| 2020-2022 |
Hospital disruption and procurement volatility during the pandemic |
| 2023-2025 |
Mature demand, generic pressure and product-mix competition |
| 2026 onward |
Stable core use with gradual substitution risk from newer myeloma strategies |
Which companies manufacture or commercialize melphalan hydrochloride?
The competitive field includes branded specialty-pharmaceutical companies and generic injectable manufacturers.
Acrotech Biopharma
Acrotech commercializes Evomela in the United States. The product is positioned as a differentiated injectable melphalan hydrochloride formulation for transplant conditioning and multiple myeloma palliation.
Acrotech is part of the Aurobindo Pharma group. Its commercial strategy has focused on hospital-administered specialty medicines, oncology products and products with complex handling or supply characteristics [4, 5].
Generic manufacturers
Generic melphalan hydrochloride has been marketed or supplied by multiple manufacturers over time. The relevant competitive set can change as FDA approvals, manufacturing arrangements, discontinuations and shortages alter availability.
Generic competition generally operates through:
- Direct hospital contracting.
- Specialty distributors.
- Group purchasing organizations.
- Tender pricing outside the United States.
- Regional supply agreements.
The key competitive variable is often supply reliability rather than clinical differentiation. Injectable oncology products can experience intermittent shortages because of limited manufacturing capacity, raw-material constraints and quality-control events [6].
What FDA regulatory status applies to melphalan hydrochloride?
Melphalan hydrochloride is an FDA-approved small-molecule oncology drug. It is not a biologic and does not have biosimilar competition.
The regulatory pathways include:
| Product category |
FDA pathway |
Commercial implication |
| Evomela |
Section 505(b)(2) new drug application pathway |
Supports a differentiated formulation and branded positioning |
| Conventional injectable products |
Abbreviated new drug applications where applicable |
Enables generic competition |
| Oral melphalan |
Legacy small-molecule product pathway |
Separate dosage form and substitution dynamics |
| Melphalan flufenamide |
Separate NDA and clinical program |
Not interchangeable with melphalan hydrochloride |
Evomela’s formulation was designed to improve preparation and stability compared with conventional melphalan hydrochloride. Its approval therefore created formulation-level differentiation without changing the underlying active pharmaceutical ingredient [1].
What is the Orange Book status of melphalan hydrochloride?
The FDA Orange Book identifies approved drug products, reference-listed drugs and, where applicable, patent and exclusivity information. Melphalan hydrochloride products must be assessed individually because the regulatory status differs by dosage form, manufacturer and application.
The main Orange Book questions for a commercial or litigation review are:
- Whether Evomela has current patent listings.
- Whether a generic applicant has certified against listed patents.
- Whether any listed patents cover formulation, stability or use.
- Whether listed exclusivity has expired.
- Whether the product is therapeutically equivalent to a reference-listed product.
- Whether an ANDA applicant can obtain a rating that permits substitution.
Evomela’s seven-year orphan-drug exclusivity period began with its 2016 approval and would have expired in 2023, subject to the scope of the approved indication and any applicable regulatory provisions [1, 7]. Orphan exclusivity does not prevent all competition outside the protected indication and is separate from patent protection.
What patents protect melphalan hydrochloride products?
Protection for melphalan hydrochloride is more likely to arise from formulation and manufacturing patents than from composition-of-matter rights. The underlying active ingredient is an old molecule, so basic molecule-level exclusivity is no longer commercially relevant.
Potential protection categories include:
Formulation patents
These may cover:
- Stabilized melphalan hydrochloride compositions.
- Solvent systems.
- Lyophilized powders.
- Reconstitution procedures.
- Concentration ranges.
- Storage stability.
- Ready-to-use or extended-stability presentations.
Formulation protection is commercially important because injectable melphalan has historically presented stability and handling challenges. A patent that covers the commercial formulation can delay direct substitution even after the active ingredient is generic.
Method-of-use patents
Method-of-use claims may address:
- High-dose conditioning before autologous stem-cell transplantation.
- Treatment of multiple myeloma.
- Administration schedules.
- Patient-selection criteria.
- Combination use with transplantation or supportive-care regimens.
Their value is narrower than composition patents because generic applicants may design around a patented indication or rely on a Section viii statement that omits the protected use, where applicable.
Manufacturing patents
Manufacturing and process claims may cover:
- Purification of melphalan hydrochloride.
- Control of degradation products.
- Crystallization.
- Lyophilization.
- Sterility and injectable preparation.
- Packaging and stability controls.
These rights can increase the cost and time required for generic development, but they usually do not create broad market exclusivity unless they cover the only commercially practical process.
When did melphalan hydrochloride lose exclusivity?
The original melphalan molecule lost meaningful patent exclusivity decades ago. The more relevant modern exclusivity event was Evomela’s approval in 2016.
| Exclusivity type |
Approximate status |
| Original molecule patents |
Expired |
| Evomela orphan-drug exclusivity |
Began in 2016; generally expired in 2023 |
| Formulation patents |
Must be assessed against current FDA and patent records |
| Generic entry |
Available in the conventional injectable segment |
| Biosimilar exclusivity |
Not applicable |
The expiration of orphan exclusivity did not automatically eliminate formulation-based commercial protection. It did, however, remove one important regulatory barrier to competing products for the protected indication.
Are there Paragraph IV challenges to Evomela?
Paragraph IV risk depends on the patents listed for the relevant FDA application and the certifications submitted by ANDA applicants. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed.
For melphalan hydrochloride, the commercial significance of a Paragraph IV challenge depends on whether the target is:
- The active ingredient.
- The injectable formulation.
- Stability characteristics.
- A specific indication.
- A manufacturing process.
- A dosage or concentration.
A challenge to a formulation patent can be more commercially meaningful than a challenge to a use patent because a successful ANDA may compete across the principal hospital use. A use-patent challenge may produce narrower exposure because the applicant can omit the protected indication.
A complete current litigation assessment requires matching FDA Orange Book listings with PACER complaints, docket activity and settlement terms. The commercially relevant conclusion is that conventional generic entry is already a structural feature of the market, while Evomela-specific entry risk turns on formulation patents and regulatory equivalence.
What patent litigation and settlement agreements affect the market?
Melphalan hydrochloride litigation is less economically prominent than litigation involving major patented oral oncology products or biologics. The main dispute categories are likely to involve:
- ANDA patent infringement.
- Formulation validity.
- Infringement of stability claims.
- Paragraph IV notice letters.
- Regulatory exclusivity overlap.
- Manufacturing-process disputes.
Settlement agreements, if reached, can establish an agreed generic launch date, license terms, supply rights or restrictions on the approved indication. For a low-volume injectable product, settlement economics are usually driven by the value of the formulation premium and the expected hospital price erosion after entry.
How strong is the melphalan hydrochloride patent estate?
The patent estate is structurally weaker than the estate for a recently launched small molecule.
Strengths
- Formulation patents can protect a commercially differentiated injectable product.
- Hospital workflow improvements may support premium pricing.
- Manufacturing complexity can deter smaller generic entrants.
- Supply reliability can preserve market share after legal exclusivity ends.
Weaknesses
- The active ingredient is old and widely known.
- Generic injectable competition is feasible.
- Method-of-use claims may be narrow or design-aroundable.
- Orphan-drug exclusivity has expired for the 2016 Evomela approval.
- Hospital purchasing organizations exert strong price pressure.
Overall, melphalan hydrochloride has a moderate commercial-defense profile for a differentiated formulation and a weak exclusivity profile for the active ingredient itself.
What generic entry risks exist for melphalan hydrochloride?
Generic-entry risk is highest in conventional injectable melphalan and lower, but not absent, for Evomela.
Conventional generic risk
Generic suppliers can compete on price when their products meet hospital requirements for:
- Concentration.
- Reconstitution time.
- Stability.
- Packaging.
- Storage.
- Therapeutic equivalence.
- Reliable supply.
This segment is structurally exposed to price erosion.
Evomela risk
Evomela faces several forms of competition:
- Direct generic competition against the formulation, if an ANDA applicant can establish equivalence or avoid relevant patents.
- Substitution with conventional melphalan hydrochloride.
- Contracting pressure from hospitals.
- Lower transplant volumes.
- Use of alternative conditioning protocols.
- Treatment migration toward CAR-T and bispecific therapies.
The product’s defense is strongest when hospitals value preparation simplicity and stability enough to offset acquisition-price differences.
How does melphalan hydrochloride compare with competing conditioning drugs?
| Drug or regimen |
Primary role |
Competitive position |
| Melphalan hydrochloride |
Standard conditioning for multiple myeloma autologous transplant |
Strong clinical familiarity and established use |
| Busulfan-based regimens |
Conditioning in selected transplant settings |
More relevant in other hematologic diseases |
| Cyclophosphamide combinations |
Conditioning or mobilization-related use |
Often part of combination protocols |
| Total-body irradiation-based regimens |
Selected transplant protocols |
Limited by toxicity and institutional practice |
| CAR-T therapy |
Disease treatment, not conventional conditioning replacement |
Can reduce or delay transplant in selected patients |
| Bispecific antibodies |
Relapsed or refractory myeloma treatment |
Compete for treatment sequencing and later-line demand |
Melphalan remains difficult to displace in the standard autologous transplant pathway for eligible multiple myeloma patients. Its larger strategic risk is not direct substitution by a single conditioning agent. It is a gradual reduction in transplant use as advanced therapies move earlier in treatment.
What geographic markets are most important?
The United States is commercially important because Evomela has branded pricing and a substantial specialty-pharmaceutical infrastructure. Europe and other developed markets are more heavily influenced by national reimbursement, tendering and generic pricing.
Geographic differences include:
- United States: branded formulation pricing, hospital contracting and FDA exclusivity.
- Europe: centralized or national reimbursement and stronger tender pressure.
- Emerging markets: lower prices, local manufacturing and variable transplant infrastructure.
- Asia-Pacific: expanding oncology capacity but heterogeneous access to transplantation and specialty formulations.
Manufacturing and supply continuity are important across all regions. Injectable oncology markets can be vulnerable to disruptions because only a limited number of approved suppliers may support a given market at any time.
What is the investment and revenue outlook for melphalan hydrochloride?
Melphalan hydrochloride is a defensive specialty-pharmaceutical asset rather than a high-growth oncology franchise.
Revenue-supporting factors include:
- Recurring transplant demand.
- Multiple myeloma incidence growth.
- Established physician familiarity.
- Premium pricing for differentiated formulations.
- High switching costs created by hospital protocols and supply qualification.
Revenue-reducing factors include:
- Generic price competition.
- Expired regulatory exclusivity.
- Limited patient expansion from an old cytotoxic agent.
- Hospital procurement pressure.
- Increasing use of CAR-T and bispecific therapies.
- Potential movement toward outpatient and lower-cost treatment models.
The most credible base case is stable to modestly declining revenue for the overall active ingredient, with better resilience for a formulation that improves pharmacy operations. Upside would require increased transplant volumes, supply shortages affecting competitors, successful geographic expansion or stronger-than-expected retention of the premium formulation. Downside would follow accelerated generic substitution or a faster decline in autologous transplantation.
Key Takeaways
- Melphalan hydrochloride is a mature, low-growth oncology market anchored by autologous stem-cell transplantation.
- Evomela is the principal differentiated U.S. formulation and was approved in 2016.
- Evomela’s orphan-drug exclusivity generally expired in 2023.
- The active ingredient has no meaningful remaining composition-of-matter exclusivity.
- Formulation, stability and manufacturing patents are more commercially relevant than molecule patents.
- Conventional generic competition creates persistent price pressure.
- No biosimilar risk applies because melphalan hydrochloride is a small molecule.
- CAR-T and bispecific therapies create long-term treatment-sequencing risk but have not eliminated melphalan’s role in transplant conditioning.
- Public financial data do not isolate global melphalan hydrochloride sales, so product-level revenue analysis should focus on disclosed Evomela performance, hospital purchasing data and procedure-volume trends.
- The strongest commercial asset is a reliable, differentiated injectable formulation, not the melphalan molecule itself.
FAQs
Is melphalan hydrochloride the same as Pepaxto?
No. Melphalan hydrochloride and melphalan flufenamide are different molecules. Pepaxto was the brand name for melphalan flufenamide.
Is melphalan hydrochloride still used in multiple myeloma?
Yes. High-dose melphalan hydrochloride remains a standard conditioning treatment before autologous stem-cell transplantation in eligible multiple myeloma patients.
Does melphalan hydrochloride have biosimilars?
No. Melphalan hydrochloride is a small-molecule drug. Competition comes from generic drug products, not biosimilars.
Can a generic substitute for Evomela automatically?
Not necessarily. Substitution depends on FDA product ratings, formulation equivalence, labeling, pharmacy requirements and any enforceable patent rights.
What is the biggest long-term threat to melphalan hydrochloride revenue?
The principal long-term threat is declining use of autologous transplantation as CAR-T therapies and bispecific antibodies move into earlier lines of multiple myeloma treatment.
References
- U.S. Food and Drug Administration. (2016). Evomela (melphalan hydrochloride) for injection prescribing information.
- U.S. Food and Drug Administration. (2024). FDA approves withdrawal of melphalan flufenamide indication and related regulatory actions.
- National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Multiple myeloma.
- Acrotech Biopharma. (n.d.). Evomela product information.
- Aurobindo Pharma Limited. (2024). Annual report 2023-2024.
- U.S. Food and Drug Administration. (n.d.). Drug shortages and supply information for injectable oncology products.
- U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity database.
